Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Change in Energy Pathway Enables Malignant Melanoma Cells to Survive BRAF Inhibition

By BiotechDaily International staff writers
Posted on 18 Mar 2013
A recent paper showed that BRAF (v-raf murine sarcoma viral oncogene homolog B1) -positive metastatic malignant melanoma cells survive treatment with BRAF inhibitors by increasing dependence on mitochondrial activity with concomitant change of energy production to the oxidative phosphorylation pathway.

The protein encoded by the BRAF gene plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene have been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small-cell lung carcinoma, and lung adenocarcinoma. Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis.

Investigators at Harvard University Medical School (Boston, MA, USA) reported in the March 7, 2013, online edition of the journal Cancer Cell that BRAF inhibition induced an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitochondrial master regulator, PGC1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC-1alpha is a transcriptional coactivator that regulates the genes involved in energy metabolism and provides a direct link between external physiological stimuli and the regulation of mitochondrial biogenesis.

The investigators showed that a target of BRAF, the melanocyte lineage factor MITF, directly regulated the expression of PGC1alpha. Melanomas with activation of the BRAF/MAPK pathway had suppressed levels of MITF and PGC1alpha and decreased oxidative metabolism. Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors rendered them addicted to oxidative phosphorylation.

"We were surprised to find that melanoma cells treated with the BRAF inhibitor vemurafenib dramatically change the way they produce energy to stay alive," said Dr. David E. Fisher, professor of dermatology at Harvard University Medical School. "While current BRAF inhibitor treatment is a major improvement – shrinking tumors in most patients and extending survival for several months – patients eventually relapse. So there is an ongoing need to improve both the magnitude and durability of these responses."

"These findings suggest that combination treatment with mitochondrial inhibitors could improve the efficacy of BRAF inhibitors in malignant melanoma," said Dr. Fisher. "Several small molecules that target mitochondrial metabolism have been identified by investigators here at Harvard and elsewhere, and laboratory investigations of specific combinations of BRAF inhibitors with mitochondrial antagonists are currently underway."

Related Links:

Harvard University Medical School



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.